Evotec starts Phase 1 trial for Jst-018 orthopoxvirus antibodies
Evotec initiated a Phase 1 trial for Jst-018 antibodies targeting orthopoxviruses.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.